• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME.

作者信息

Avery Robert L, Csaky Karl G, Westenskow Peter, Stoilov Ivaylo, Diack Cheikh

机构信息

California Retina Consultants, Santa Barbara, CA, USA.

Retina Foundation of the Southwest, Dallas, TX, USA.

出版信息

Transl Vis Sci Technol. 2023 Oct 3;12(10):6. doi: 10.1167/tvst.12.10.6.

DOI:10.1167/tvst.12.10.6
PMID:37801301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10561785/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3173/10561785/a723d99b5628/tvst-12-10-6-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3173/10561785/a723d99b5628/tvst-12-10-6-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3173/10561785/a723d99b5628/tvst-12-10-6-f001.jpg

相似文献

1
Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME.阿柏西普不能抑制湿性年龄相关性黄斑变性或糖尿病性黄斑水肿患者的血管生成素-2。
Transl Vis Sci Technol. 2023 Oct 3;12(10):6. doi: 10.1167/tvst.12.10.6.
2
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.年龄相关性黄斑变性和糖尿病性黄斑水肿患者的治疗模式：迪拜真实世界的理赔分析。
PLoS One. 2021 Jul 13;16(7):e0254569. doi: 10.1371/journal.pone.0254569. eCollection 2021.
3
Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.真实世界中雷珠单抗和阿柏西普治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿的注射频率和费用。
J Manag Care Spec Pharm. 2020 Mar;26(3):253-266. doi: 10.18553/jmcp.2020.19245. Epub 2020 Feb 5.
4
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.玻璃体内注射阿柏西普、贝伐单抗或雷珠单抗治疗伴有视力损害的累及中心的糖尿病性黄斑水肿后持续性黄斑增厚：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565.
5
Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.利用患者层面的数据进行糖尿病性黄斑水肿患者视力损害的有意义的跨试验比较。
Adv Ther. 2016 Apr;33(4):597-609. doi: 10.1007/s12325-016-0310-0. Epub 2016 Mar 7.
6
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia.在澳大利亚进行的一项回顾性队列研究：雷珠单抗和阿柏西普治疗新生血管性年龄相关性黄斑变性的配药模式。
Adv Ther. 2017 Dec;34(12):2585-2600. doi: 10.1007/s12325-017-0624-6. Epub 2017 Nov 21.
7
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.阿柏西普、贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的比较：数据外推至临床实践
JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.
8
Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.从美国角度评估雷珠单抗和阿柏西普治疗糖尿病性黄斑水肿的成本效果：Protocol T 研究两年数据分析。
J Med Econ. 2020 Mar;23(3):287-296. doi: 10.1080/13696998.2019.1666855. Epub 2019 Nov 4.
9
Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性的 12 个月疗效观察：一项观察性研究数据。
Ophthalmology. 2016 Dec;123(12):2545-2553. doi: 10.1016/j.ophtha.2016.08.016. Epub 2016 Oct 1.
10
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).新生血管性年龄相关性黄斑变性的黄斑萎缩：比较雷珠单抗和阿柏西普的随机临床试验（RIVAL 研究）。
Ophthalmology. 2020 Feb;127(2):198-210. doi: 10.1016/j.ophtha.2019.08.023. Epub 2019 Aug 27.

引用本文的文献

1
Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration.关于法西单抗转换治疗难治性新生血管性年龄相关性黄斑变性的真实世界数据。
Life (Basel). 2024 Jan 29;14(2):193. doi: 10.3390/life14020193.

本文引用的文献

1
Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model.阿柏西普抑制兔视网膜血管高通透性模型中的血管生成素-2。
Transl Vis Sci Technol. 2023 May 1;12(5):17. doi: 10.1167/tvst.12.5.17.
2
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.泰纳亚和卢塞恩：法西单抗治疗新生血管性年龄相关性黄斑变性3期临床试验的基本原理与设计
Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec.
3
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
约塞米蒂和莱茵河：法西单抗治疗糖尿病性黄斑水肿的3期随机临床试验：研究设计与原理
Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar.
4
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.在糖尿病性黄斑水肿（YOSEMITE 和 RHINE）患者中，每 16 周进行一次玻璃体腔内 faricimab 延长给药的疗效、持久性和安全性：两项随机、双盲、3 期试验。
Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24.
5
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.玻璃体腔内 faricimab 每 16 周治疗新生血管性年龄相关性黄斑变性的疗效、持久性和安全性（TENAYA 和 LUCERNE）：两项随机、双盲、3 期、非劣效性试验。
Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24.
6
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK 和 HARRIER：贝鲁珠单抗治疗新生血管性年龄相关性黄斑变性的 3 期、多中心、随机、双盲试验。
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
7
Retinal vascular patterns in domestic animals.家畜的视网膜血管模式。
Res Vet Sci. 1989 Jul;47(1):34-42.